New pill shows promise for Hard-to-Treat blood cancers

NCT ID NCT03162536

Ongoing Disease control Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a daily oral drug called nemtabrutinib (ARQ 531) in 190 people with blood cancers like lymphoma or leukemia that have come back or not responded to prior treatment. The goal is to find a safe dose and see if the drug can shrink tumors. It is an early-phase trial, so the main focus is on safety and how the body processes the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Nemtabrutinib (ARQ 531) – a daily oral tablet

What this could lead to

If successful, this could provide a new treatment option for people with blood cancers that have stopped responding to other therapies.

What could go wrong

This is an early-phase trial (Phase 1/2) with no formal hypothesis testing. Side effects may be significant, and the drug may not shrink tumors or improve survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia B-cell neoplasm B-cell non-Hodgkin lymphoma Blood Protein Disorders cardiovascular disorder diffuse large B-cell lymphoma follicular lymphoma hematopoietic and lymphoid system neoplasm hemorrhagic disease high grade B-cell lymphoma immune system disorder immunoproliferative disorder interdigitating dendritic cell sarcoma leukemia Leukemia, B-Cell lymphatic system disorder lymphoid leukemia lymphoma Lymphoma, B-Cell, Marginal Zone lymphoproliferative syndrome mantle cell lymphoma marginal zone lymphoma monoclonal gammopathy neoplasm Neoplasms by Histologic Type non-Hodgkin lymphoma plasma cell neoplasm Recurrence Richter transformation vascular disorder vascular hemostatic disease Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA DIFFUSE LARGE B-CELL LYMPHOMA FOLLICULAR LYMPHOMA LYMPHOMA, B-CELL MANTLE CELL LYMPHOMA MARGINAL ZONE LYMPHOMA RICHTER'S TRANSFORMATION SMALL LYMPHOCYTIC LYMPHOMA WALDENSTROM MACROGLOBULINEMIA

Contacts and locations

Show contact details

Locations

Colorado Blood Cancer Institute ( Site 0225)

Denver, Colorado, 80218, United States
Duke Cancer Center ( Site 0067)

Durham, North Carolina, 27710, United States
Mayo Clinic - Rochester ( Site 0138)

Rochester, Minnesota, 58905, United States
Mayo Clinic Hospital ( Site 0140)

Scottsdale, Arizona, 85259, United States
Tennessee Oncology, PLLC ( Site 0020)

Nashville, Tennessee, 37203, United States
The Ohio State University Wexner Medical Center ( Site 0056)

Columbus, Ohio, 43210, United States
UCLA Hematology & Oncology ( Site 0017)

Los Angeles, California, 90095, United States
UT Southwestern Medical Center ( Site 0116)

Dallas, Texas, 75390-8562, United States
University of Michigan ( Site 0018)

Ann Arbor, Michigan, 48109, United States
University of Utah, Huntsman Cancer Institute ( Site 0122)

Salt Lake City, Utah, 84112, United States